Forward J.T. Miller was reportedly close to leaving the Vancouver Canucks at some point through Saturday, but he remains on its roster and at the center of trade speculation. According to ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Louis Navellier is a prominent American investor, author, and financial analyst ...

There’s also his legendary run as a spokesman for Miller Lite, with Uecker starring in so many commercials for the beer brand over the years. So as we share our favorite Uecker moments ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Copyright 2025 The Associated Press. All Rights Reserved. This cover image released by Warner Records shows “Balloonerism” by Mac Miller. (Warner Records via AP ...

The program announced on Wednesday that it signed Penn State transfer cornerback Cam Miller, the latest addition to a revamped defense heading into the 2025 season. The 6-foot, 183-pound Miller ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Stephen Miller was the architect of Donald J. Trump’s hard-line immigration agenda in his first term. Now he is back with fewer internal rivals and even more influence with the president.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025. With explosive deals out of the way, news from ...